23 November 2020
National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.” – Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital
National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies
Metabolon, Inc. Joins SOPHIA, International Research Consortium
Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics
Enlightening a Company, By Design
Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine
Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering
New partnership leveraging metabolomics to uncover reasons for frailty in aging populations
Metabolon to Provide Metabolomic Profiling for the US Veterans Administration Million Veteran Program